Inés Álvarez-Miguel

Inés Álvarez-Miguel

Auto-generated profile, based on publicly available information

Inés Álvarez-Miguel

IMDEA Energy Institute, Advanced Porous Materials Unit (APMU), Avda. Ramón de la Sagra 3, E-28935 Móstoles, Madrid, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
GLGema Lordén
Gema Lordén
ISItziar Sanjuán-García
Itziar Sanjuán-García
NPNagore De Pablo
Nagore De Pablo
CMClara Meana
Clara Meana
IAInés Alvarez-Miguel
Inés Alvarez-Miguel
María A. BalboaMaría A. Balboa
María A. Balboa
Mutations in human LPIN2 produce a disease known as Majeed syndrome, the clinical manifestations of which are ameliorated by strategies that block IL-1β or its receptor. However the role of lipin-2 during IL-1β production remains elusive. We show here that lipin-2 controls excessive IL-1β formation in primary human and mouse macrophages by several mechanisms, including activation of the inflammasome NLRP3. Lipin-2 regulates MAPK activation, which mediates synthesis of pro–IL-1β during inflammasome priming. Lipin-2 also inhibits the activation and sensitization of the purinergic receptor P2X7 and K+ efflux, apoptosis-associated speck-like protein with a CARD domain oligomerization, and caspase-1 processing, key events during inflammasome activation. Reduced levels of lipin-2 in macrophages lead to a decrease in cellular cholesterol levels. In fact, restoration of cholesterol concentrations in cells lacking lipin-2 decreases ion currents through the P2X7 receptor, and downstream events that drive IL-1β production. Furthermore, lipin-2–deficient mice exhibit increased sensitivity to high lipopolysaccharide doses. Collectively, our results unveil lipin-2 as a critical player in the negative regulation of NLRP3 inflammasome.

1 February 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LJLaura Jiménez-Pérez
Laura Jiménez-Pérez
PCPilar Cidad
Pilar Cidad
IÁInés Álvarez-Miguel
Inés Álvarez-Miguel
ASAlba Santos-Hipólito
Alba Santos-Hipólito
RTRebeca Torres-Merino
Rebeca Torres-Merino
M. Teresa Perez-GarciaM. Teresa Perez-Garcia
M. Teresa Perez-Garcia
Changes in voltage-dependent potassium channels (Kv channels) associate to proliferation in many cell types, including transfected HEK293 cells. In this system, Kv1.5 overexpression decreases proliferation while Kv1.3 expression increases it independently of K+ fluxes. To identify Kv1.3 domains involved in proliferation-associated signaling mechanism(s), we constructed chimeric Kv1.3-Kv1.5 channels and point-mutant Kv1.3 channels, which were expressed as GFP- or cherry-fusion proteins. We studied their trafficking and functional expression, combining immunocytochemical and electrophysiological methods, and their impact on cell proliferation. We found that the C-terminus is necessary for Kv1.3-induced proliferation. We distinguished two residues (Y447 and S459) whose mutation to alanine abolished proliferation. The insertion into Kv1.5 of a sequence comprising these two residues increased proliferation rate. Moreover, Kv1.3 voltage-dependent transitions from closed to open conformation induced MEK-ERK1/2-dependent Y447 phosphorylation. We conclude that the mechanisms for Kv1.3-induced proliferation involve the accessibility of key docking sites at the C-terminus. For one of these sites (Y447) we demonstrated the contribution of MEK/ERK dependent phosphorylation, which is regulated by voltage-induced conformational changes.

29 December 2016 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
IÁInés Álvarez‐Miguel
Inés Álvarez‐Miguel
PCPilar Cidad
Pilar Cidad
M. Teresa Perez-GarciaM. Teresa Perez-Garcia
M. Teresa Perez-Garcia
JLJosé Ramón López‐López
José Ramón López‐López

25 September 2024 in Function
Verified
Journal Article
Open access
PDF file
NDNuria Daghbouche-Rubio
Nuria Daghbouche-Rubio
IÁInés Álvarez-Miguel
Inés Álvarez-Miguel
VFVictor Alejandro Flores
Victor Alejandro Flores
JRJorge Rojo-Mencía
Jorge Rojo-Mencía
MNManuel Navedo
Manuel Navedo
JLJosé R López-López
José R López-López
Essential hypertension (HT) is a highly prevalent cardiovascular disease of unclear physiopathology. Pharmacological studies suggest that purinergic P2Y6 receptors (P2ry6) play important roles in cardiovascular function and may contribute to angiotensin II (AgtII) pathophysiological effects. Here, we tested the hypothesis that functional coupling between P2ry6 and AgtII receptors mediates altered vascular reactivity in HT. For this, a multipronged approach was implemented using mesenteric vascular smooth muscle cells (VSMCs) and arteries from Blood Pressure Normal (BPN) and Blood Pressure High (BPH) mice. Differential transcriptome profiling of mesenteric artery VSMCs identified P2ry6 purinergic receptor mRNA as one of the top upregulated transcripts in BPH. P2Y receptor activation elicited distinct vascular responses in mesenteric arteries from BPN and BPH mice. Accordingly, 10 µm UTP produced a contraction close to half-maximal activation in BPH arteries but no response in BPN vessels. AgtII-induced contraction was also higher in BPH mice despite having lower AgtII receptor type-1 (Agtr1) expression and was sensitive to P2ry6 modulators. Proximity ligation assay and super-resolution microscopy showed closer localization of Agtr1 and P2ry6 at/near the membrane of BPH mice. This proximal association was reduced in BPN mice, suggesting a functional role for Agtr1-P2ry6 complexes in the hypertensive phenotype. Intriguingly, BPN mice were resistant to AgtII-induced HT and showed reduced P2ry6 expression in VSMCs. Altogether, results suggest that increased functional coupling between P2ry6 and Agtr1 may contribute to enhanced vascular reactivity during HT. In this regard, blocking P2ry6 could be a potential pharmacological strategy to treat HT.

11 June 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
IÁInés Álvarez-Miguel
Inés Álvarez-Miguel
BFBeatrice Fodor
Beatrice Fodor
GLGuillermo G. López
Guillermo G. López
CBCatalina Biglione
Catalina Biglione
EGErik Svensson Grape
Erik Svensson Grape
PHPatricia Horcajada
Patricia Horcajada
The SARS-CoV-2 (COVID-19) pandemic outbreak led to enormous social and economic repercussions worldwide, felt even to this date, making the design of new therapies to combat fast-spreading viruses an imperative task. In the face of this, diverse cutting-edge nanotechnologies have risen as promising tools to treat infectious diseases such as COVID-19, as well as challenging illnesses such as cancer and diabetes. Aside from these applications, nanoscale metal-organic frameworks (nanoMOFs) have attracted much attention as novel efficient drug delivery systems for diverse pathologies. However, their potential as anti-COVID-19 therapeutic agents has not been investigated. Herein, we propose a pioneering anti-COVID MOF approach by studying their potential as safe and intrinsically antiviral agents through screening various nanoMOF. The iron(III)-trimesate MIL-100 showed a noteworthy antiviral effect against SARS-CoV-2 at the micromolar range, ensuring a high biocompatibility profile (90% of viability) in a real infected human cellular scenario. This research effectively paves the way toward novel antiviral therapies based on nanoMOFs, not only against SARS-CoV-2 but also against other challenging infectious and/or pulmonary diseases.

11 November 2019 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
LÁLucía Álvarez-Miguel
Lucía Álvarez-Miguel
IÁInés Álvarez-Miguel
Inés Álvarez-Miguel
Celedonio AlvarezCeledonio Alvarez
Celedonio Alvarez
Celedonio AlvarezCeledonio Alvarez
Celedonio Alvarez
GRGuillaume Rogez
Guillaume Rogez
DMDaniel Miguel
Daniel Miguel
The template effect in K2(N,O) chelated Cu(ii) complexes can promote C–C or C–N coupling products.